Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Seer has announced a co-marketing and sales agreement with Thermo Fisher Scientific to jointly promote Seer's Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. Under this non-exclusive agreement, Thermo Fisher's global sales force will be able to quote and sell Seer's Proteograph Product Suite starting in early 2025. The collaboration includes joint marketing activities and research studies to showcase their integrated proteomic platforms. The partnership aims to provide researchers with an integrated solution for deep, rapid, and unbiased proteomic analysis at scale.
Seer ha annunciato un accordo di co-marketing e vendite con Thermo Fisher Scientific per promuovere congiuntamente la suite di prodotti Proteograph™ di Seer insieme agli spettrometri di massa Thermo Scientific Orbitrap Astral™. Sotto questo accordo non esclusivo, la forza vendita globale di Thermo Fisher potrà quotare e vendere la suite di prodotti Proteograph di Seer a partire dai primi mesi del 2025. La collaborazione include attività di marketing congiunte e studi di ricerca per mettere in mostra le loro piattaforme proteomiche integrate. L'obiettivo della partnership è fornire ai ricercatori una soluzione integrata per analisi proteomiche profonde, rapide e imparziali su larga scala.
Seer ha anunciado un acuerdo de co-marketing y ventas con Thermo Fisher Scientific para promover conjuntamente la suite de productos Proteograph™ de Seer junto con los espectrómetros de masas Thermo Scientific Orbitrap Astral™. Bajo este acuerdo no exclusivo, la fuerza de ventas global de Thermo Fisher podrá cotizar y vender la suite de productos Proteograph de Seer a partir de principios de 2025. La colaboración incluye actividades de marketing conjuntas y estudios de investigación para mostrar sus plataformas proteómicas integradas. La asociación tiene como objetivo proporcionar a los investigadores una solución integrada para análisis proteómicos profundos, rápidos e imparciales a gran escala.
Seer는 Thermo Fisher Scientific와 공동 마케팅 및 판매 계약을 체결하여 Seer의 Proteograph™ 제품군과 Thermo Scientific Orbitrap Astral™ 질량 분석기를 함께 홍보합니다. 이 비독점 계약에 따라 Thermo Fisher의 글로벌 영업팀은 2025년 초부터 Seer의 Proteograph 제품군을 인용하고 판매할 수 있게 됩니다. 협력은 통합 프로테오믹 플랫폼을 선보이기 위한 공동 마케팅 활동 및 연구를 포함합니다. 이 파트너십의 목표는 연구자들에게 심층적이고 신속하며 공정한 대규모 프로테오믹 분석을 위한 통합 솔루션을 제공하는 것입니다.
Seer a annoncé un accord de co-marketing et de vente avec Thermo Fisher Scientific pour promouvoir conjointement la suite de produits Proteograph™ de Seer aux côtés des spectromètres de masse Thermo Scientific Orbitrap Astral™. Dans le cadre de cet accord non exclusif, la force de vente mondiale de Thermo Fisher pourra proposer et vendre la suite de produits Proteograph de Seer à partir du début de 2025. La collaboration inclut des activités marketing conjointes et des études de recherche pour mettre en valeur leurs plateformes protéomiques intégrées. L'objectif de ce partenariat est de fournir aux chercheurs une solution intégrée pour des analyses protéomiques profondes, rapides et impartiales à grande échelle.
Seer hat eine Co-Marketing- und Vertriebsvereinbarung mit Thermo Fisher Scientific bekannt gegeben, um die Proteograph™ Produktpalette von Seer gemeinsam mit den Thermo Scientific Orbitrap Astral™ Massenspektrometern zu bewerben. Im Rahmen dieser nicht-exklusiven Vereinbarung wird die globale Vertriebsforce von Thermo Fisher in der Lage sein, die Proteograph Produktpalette von Seer ab Anfang 2025 anzubieten und zu verkaufen. Die Zusammenarbeit umfasst gemeinsame Marketingaktivitäten und Forschungsstudien, um ihre integrierten proteomischen Plattformen zu präsentieren. Das Ziel der Partnerschaft ist es, Forschern eine integrierte Lösung für Tiefen-, Schnell- und unvoreingenommene proteomische Analysen in großem Maßstab bereitzustellen.
- Strategic partnership with industry leader Thermo Fisher Scientific expands global market reach
- Access to Thermo Fisher's global sales force for Proteograph Product Suite distribution
- Integration of complementary technologies creates comprehensive end-to-end solution
- Implementation of partnership delayed until early 2025
- Non-exclusive agreement allows Thermo Fisher to maintain partnerships with competitors
Insights
This strategic partnership significantly enhances SEER's market position and distribution capabilities. The collaboration with Thermo Fisher, a $200+ billion market cap industry leader, provides SEER access to an extensive global sales network and customer base. The integration of SEER's Proteograph with Thermo's Orbitrap Astral creates a compelling end-to-end proteomics solution that could accelerate market adoption.
The non-exclusive agreement allows Thermo Fisher's sales force to quote and sell SEER's complete product suite, potentially driving substantial revenue growth starting in early 2025. The joint marketing initiatives and research collaborations should strengthen SEER's market presence and validate its technology platform. For a small-cap company (<$150M market cap), this partnership represents a major commercial milestone that could significantly impact future growth trajectory.
The technical synergy between SEER's Proteograph and Thermo's Orbitrap Astral creates a powerful integrated solution for proteomics research. The Proteograph's unique nanoparticle technology for unbiased protein sampling complements the high-resolution mass spectrometry capabilities of the Orbitrap Astral. This combination addresses key challenges in proteomics:
- Improved sample preparation automation
- Enhanced protein detection sensitivity
- Streamlined workflow integration
- Scalable analysis capabilities
The planned workflow improvements and joint research studies, particularly in population-scale studies, could establish new industry standards for proteomic analysis, potentially leading to breakthrough discoveries in understanding disease mechanisms.
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world leader in serving science, to jointly promote Seer’s Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. This strategic collaboration aims to accelerate the adoption of innovative proteomic technologies, offering researchers an integrated solution for deep, rapid, and unbiased proteomic analysis at scale.
Under this non-exclusive agreement, Thermo Fisher’s global sales force will have the ability to quote and sell Seer’s Proteograph Product Suite, which includes an automation instrument, proprietary engineered nanoparticles, and software analysis suite, enhancing the accessibility of this innovative technology to life science researchers worldwide. The integration is set to commence in early 2025, further expanding the reach of Seer’s platform. The collaboration will also enable Seer and Thermo Fisher to conduct joint marketing activities, including conference promotions, seminars, and webinars, to showcase the combined power of their proteomic platforms.
“This collaboration represents a pivotal step in our mission to transform proteomics by integrating our Proteograph Product Suite with Thermo Fisher’s Orbitrap Astral mass spectrometers,” said Omid Farokhzad, CEO and Chair of Seer. “Thermo Fisher mass spectrometers set the gold standard for proteomics. By enabling Thermo Fisher customers to acquire the Proteograph Product Suite in conjunction with an Orbitrap Astral, we are expanding access to these powerful tools and setting a new standard in proteomics that has the potential to accelerate scientific discoveries and ultimately improve human health.”
The companies will work together to improve workflows, creating a seamless sample-to-data experience that integrates the Proteograph and Astral technologies. The combination of the Proteograph Product Suite and Orbitrap Astral has generated exciting data for academic and commercial customers. Seer and Thermo Fisher plan to collaborate on additional joint research studies, including population scale studies, to demonstrate the comprehensive capabilities of their combined platforms, further solidifying their commitment to advancing the field of proteomics.
“This agreement builds on our existing partnership with Seer and represents a strong advancement in accelerating innovation in proteomics,” said John Lesica, President, Chromatography and Mass Spectrometry, Thermo Fisher Scientific. “By aligning our technologies, we are providing our customers with a scalable end-to-end solution to enable comprehensive proteomic insights, ultimately driving breakthroughs in understanding human biology and disease.”
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the adoption of Seer’s products and the benefits of the collaboration. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Seer Media Inquiries:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
What is the new partnership between Seer (SEER) and Thermo Fisher Scientific?
How will the Seer (SEER) and Thermo Fisher Scientific partnership affect product distribution?
What are the main objectives of the Seer (SEER) and Thermo Fisher Scientific collaboration?
